title: [Genetic screening of multiple endocrine neoplasia type 2: experience of the USP Endocrine Genetics Unit].
abstract: Multiple endocrine neoplasia type 2 (MEN-2) is an inherited tumor syndrome that includes medullary thyroid carcinoma (MTC), primary hyperparathyroidism, pheochromocytoma and other non-endocrine diseases. Since the first RET missense mutations in association with MEN-2 were identified, RET mutation analysis had a great impact in the clinical management of MEN-2, such as in early diagnosis and treatment of MTC. Presently, early total thyroidectomy provides real cure of MTC for cases in which molecular diagnosis has been performed at early ages. After RET mutation identification, family members should be screened for this mutation by using methods as DGGE, SSCP, restriction enzyme, genetic sequencing or mini-sequencing. In this paper, we briefly review our experience with the direct RET gene sequencing and DGGE approaches. In 50 typical MEN-2 patients analyzed using both methods, we found no false results suggesting that DGGE is a reliable screening method for RET proto-oncogene mutation analysis.
authors.affiliation: Unidade de Endocrinologia Genética, Clínica Médica, Faculdade de Medicina, Universidade de São Paulo, SP.
authors.forename: Marcelo A C G dos
authors.initials: MA
authors.lastname: Santos
authors.forename: Adriana Bezerra
authors.initials: AB
authors.lastname: Nunes
authors.forename: Neusa
authors.initials: N
authors.lastname: Abelin
authors.forename: Marilza C L
authors.initials: MC
authors.lastname: Ezabella
authors.forename: Rodrigo de Almeida
authors.initials: Rde A
authors.lastname: Toledo
authors.forename: Delmar
authors.initials: D M
authors.lastname: Lourenço
authors.forename: Cesar Yoiti
authors.initials: CY
authors.lastname: Hayashida
authors.forename: Ivone Izabel M da
authors.initials: II
authors.lastname: Fonseca
authors.forename: Sergio P de Almeida
authors.initials: SP
authors.lastname: Toledo
mesh_terms: D000465:Algorithms; D018276:Carcinoma, Medullary / Q000175:diagnosis* / Q000235:genetics; D005819:Genetic Markers; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D008969:Molecular Sequence Data; D018813:Multiple Endocrine Neoplasia Type 2a / Q000175:diagnosis* / Q000235:genetics; D009154:Mutation / Q000235:genetics*; D010641:Phenotype; D000090063:Proto-Oncogene Mas; D051096:Proto-Oncogene Proteins c-ret / Q000235:genetics*; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000235:genetics
chemical_list: D005819:Genetic Markers; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D051096:Proto-Oncogene Proteins c-ret; C099282:RET protein, human